Financial Markets
Real Estate
Local listed Company
Overseas-listed Company
Foreign Company
Industrial Parks

Stocks / IPOs
 Search News  Or
CSRC approve Fosun Pharmaceutical IPO in HKSE

Apr. 12, 2012 (China Knowledge) - Shanghai Fosun Pharmaceutical (Group) Co<600196>, the medical subsidiary of Fosun International Ltd<0656>, announced today that it has received approval from the China Securities Regulatory Commission to launch an initial public offering on the Hong Kong Stock Exchange.

The company said in a statement filed with the Shanghai Stock Exchange that it plans to issue 547.5 million H shares in the deal. If an over-allotment option exercised, the firm will expand the offer to 714.15 million.

The planned H-share offering is subject to approval from the Hong Kong Stock Exchange.

Media reports said earlier that the company had cut its fundraising target to between US$600 million and US$800 million from the previous US$1 billion because of weak market condition.

Upon completion of the H-share listing, Fosun Pharmaceutical will become the second mainland pharmaceutical with shares listed in both Shanghai and Hong Kong after Shanghai Pharmaceuticals Holding Co Ltd<601607><2607>.

In 2011, Fosun Pharmaceutical saw its net profit surge 43.65% year on year to RMB 1.17 billion and its operating revenue grow 42.37% to RMB 6.49 billion.

Add this     
Copyright © "2015"

Send feedback or comments to:

For more news, financial weekly reports, business guides to China, Market Research Reports and other premium information, subscribe to China Knowledge today

To access our page on Bloomberg, type CKFI (GO)

 Our Professional Services


 News Archive
About Us | CSR | Media Center | E-Newsletter | E-Store | Contact Us | Feedback | Sitemap | Privacy Policy | Terms of Use  

           Copyright © 2014 China Knowledge Online. All Rights Reserved